Canopy Growth/$CGC
1D1W1MYTD1Y5YMAX
Capital at risk
About Canopy Growth
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
- Ticker
- $CGC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,128
- Headquarters
- Smiths Falls, Canada
- Website
- www.canopygrowth.com
Canopy Growth Metrics
BasicAdvanced
$372M
-
-$0.46
2.43
-
Price and volume
Market cap
$372M
Beta
2.43
52-week high
$2.38
52-week low
$0.84
Average daily volume
2.7M
Financial strength
Current ratio
3.037
Quick ratio
2.274
Long term debt to equity
0.34
Total debt to equity
0.403
Interest coverage (TTM)
-1.53%
Profitability
EBITDA (TTM)
-18.365
Gross margin (TTM)
28.52%
Net profit margin (TTM)
-79.22%
Operating margin (TTM)
-21.44%
Effective tax rate (TTM)
0.17%
Revenue per employee (TTM)
$182,900
Management effectiveness
Return on assets (TTM)
-3.79%
Return on equity (TTM)
-39.51%
Valuation
Price to revenue (TTM)
1.523
Price to book
0.77
Price to tangible book (TTM)
0.97
Price to free cash flow (TTM)
-5.344
Free cash flow yield (TTM)
-18.71%
Free cash flow per share (TTM)
-0.165
Growth
Revenue change (TTM)
6.81%
Earnings per share change (TTM)
-79.38%
3-year revenue growth (CAGR)
-2.55%
10-year revenue growth (CAGR)
32.23%
3-year earnings per share growth (CAGR)
-70.14%
10-year earnings per share growth (CAGR)
-3.69%
What the Analysts think about Canopy Growth
Analyst ratings (Buy, Hold, Sell) for Canopy Growth stock.
Analyst projections of the future price of Canopy Growth stock.
Bulls say / Bears say
Q1 FY2027 revenue rose 13% year on year, with growth in every business. Adjusted gross margin reached 31% and the adjusted EBITDA loss narrowed 59%, supporting management’s target of positive adjusted EBITDA during FY2027. (Canopy Growth)
The January recapitalisation left Canopy with net cash of C$131.3m at the end of FY2026, while annual free cash outflow improved to C$69.1m from C$176.6m. This gives the company more time to complete its turnaround without relying immediately on another financing. (Canopy Growth)
Canopy is widening its European medical-cannabis reach by supplying four Canadian-grown strains to the UK under its Spectrum Therapeutics brand. Renewed EU GMP certification at its Kincardine facility supports access to regulated European markets where international revenue grew 10% in Q1 FY2027. (Canopy Growth, Canopy Growth)
The improved accounting results have not yet translated into cash generation. Q1 FY2027 free cash outflow increased to C$25.7m from C$11.6m, while the company still reported a C$14.6m net loss. (Canopy Growth)
Growth remains exposed to operational and reimbursement pressures. Canopy said the Canadian government’s lower Veterans Affairs reimbursement rate partly offset medical growth, while international revenue fell 7% for FY2026 despite a strong fourth quarter after earlier European supply-chain problems. (Canopy Growth, Canopy Growth)
Canopy’s US optionality carries a material credit risk: Acreage is in default under its credit agreement and is operating under forbearance. If the restructuring fails, Canopy says it may lose its investment in Acreage and related debt, weakening the value of its Canopy USA strategy. (Last10K)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.
Canopy Growth Financial Performance
Revenues and expenses
Canopy Growth Earnings Performance
Company profitability
Upcoming events
No upcoming events
Canopy Growth News
AllArticlesVideos
Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany
Business Wire4 days ago
Canopy Growth Announces Adjournment of 2026 Annual General and Special Meeting Due to Lack of Quorum
Business Wire1 week ago
Canopy Growth Announces Extension of Proxy Voting Deadline for 2026 Annual General and Special Meeting
Business Wire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.